TriangleNCT04395677 · CITED IN SOURCE DOCUMENTS
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- ACTIVE NOT RECRUITING
- Registry last update
- 2026-02-06
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- Inclusion Criteria: Patients must meet all of the following criteria to be eligible for enrollment into the study: 1. ≥ 18 years of age 2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC 3. Positivity of ROS1 fusion is determined by the local qualified laboratories by using the FISH, RT-PCR or NGS assay, and the subject must provide archival tumor tissue sample for the confirmation by a sponsor-designated central laboratory 4. The subject is either TKI treatment naïve(Cohort A)， or has disease progression following the treatment of crizotinib （Cohort B） 5. The patient with brain metastases is either asymptomatic, or neurologically stable for at least 2 weeks prior to study entry 6. Prior therapies (including chemotherapies \[less than 3 lines of regimen\], radiotherapy \[except for palliative\], or surgery) should be completed at least 2 weeks prior to study entry. The palliative radiotherapy (≤10 times) should be completed within 48 hours prior to study entry. Any acute toxic effect must be resolved to CTCAE Grade ≤1 except for alopecia 7. At least one measurable target tumor lesion (as accessed by RECIST v1.1) that has not been irradiated 8. ECOG Performance Status: 0 or 1 9. Patient with a life expectancy ≥ 3 months based on the judgement of investigators Adequate organ functions defined by the following criteria： * Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤2.5 x ULN; or ≤5 x ULN， if there is liver metastases involvement； * Total serum bilirubin ≤1.5 x ULN； * Absolute neutrophil count（ANC） ≥1500/µL； * Platelet count≥100,000/µL； * Hemoglobin≥8.0 g/dL； * Serum creatinine ≤2 x ULN. 11. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of the pertinent aspect of the study 12. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures 13. Male and female patients of childbearing potential must agree to sue effective methods of contraception throughout the study and for 90 days after the last dose of study medication. Exclusion Criteria: Patient presenting with any of the following criteria will not be included in the study： 1. Current participation in other therapeutic investigational studies 2. Previous participation in the treatment or clinical trials of other ROS1-TKIs (except for crizotinib) 3. Previous participation in the treatment and clinical trials of ALK or NTRK fusion gene targeted therapies. 4. Spinal cord compression unless the patient demonstrates good pain control and stabilization or recovery of neurological function, carcinomatous meningitis or leptomeningeal disease 5. Patients with interstitial fibrosis or interstitial lung disease 6. Any one of the following currently or in the previous 3 months: myocardial infarction, severe/unstable angina, coronary/ peripheral artery bypass graft, congestive heart failure or cerebrovascular accident including transient ischemic attack 7. Ongoing cardiac dysrhythmias of NCI CTCAE (v5.0) Grade≥2, uncontrolled atrial fibrillation of any grade, or QTc interval\>470 microsec 8. Pregnancy or breastfeeding 9. Current use of food or drugs that are known strong CYP3A inhibitors, including (but not limited to) atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, grapefruit or grapefruit juice. 10. Current use of drugs that are known strong CYP3A4 inducers, including (but not limited to) carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St John's Wort 11. Current use of drugs that are known CYP3A4 substrates with narrow therapeutic indices, including (but not limited to) dihydroergotamine, ergotamine, pimozide, astemizole, cisapride, and terfenadine. 12. Current use of drugs that are known to induce QTc prolongation 13. Systematic treatment with anti-cancer therapy, including any Traditional Chinese Medicine (TCM)with anti-tumor effect indicated in the prescription information. 14. Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in situ cervical cancer, and presumed cured prostate cancer) within the last 3 years 15. Clinically active viral disease with positivity of serum HIV, HBV, HCV, RPR testing 16. Difficult to swallow which may significantly impact drug absorption 17. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation in the judgement of investigator and sponsor
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Single-arm trial whereby all consented, enrolled, eligible patients receive AB-106
- intervention Names
- Drug: AB-106
- label
- AB-106 （DS-6051b）
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- AB-106 （DS-6051b）
- description
- Stage 1: 400mg QD for 3 patients and 600mg QD for 3 patients Stage 2: 600mg QD
- name
- AB-106
- other Names
- DS-6051b
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 173
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Best overall response (BOR) based on independent radiology review by Independent Review Committee(IRC) according to RECIST 1.1
- measure
- Best overall response (BOR) by IRC
- time Frame
- 6 months
- secondary Outcomes
- description
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
- measure
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
- time Frame
- 25 months
- description
- After the medicine, the number of patients with ECG QT Interval and the rate of patients with clinical significant
- measure
- Rate of ECG QT Interval prolongation patients in all patients
- time Frame
- 25 months
- description
- The Cmax of Cycle1Day1 and Cycle1Day15 will be assessed, (each cycle is 21 days)
- measure
- Maximum Plasma Concentration [Cmax]
- time Frame
- Day 1 to Cycle1Day15
- description
- The AUCτ of Cycle1Day1 and Cycle1Day15 will be assessed, (each cycle is 21 days)
- measure
- Area under the curve from time zero to τ (dose interval τ is 24 h in this study) [AUCτ]
- time Frame
- Day 1 to Cycle1Day15
- description
- The Cav of Cycle1Day1 and Cycle1Day15 will be assessed, (each cycle is 21 days)
- measure
- Average plasma concentration at steady state over dosing interval [Cav]
- time Frame
- Day 1 to Cycle1Day15
- description
- The Cthrough of Cycle1Day1 and Cycle1Day15 will be assessed, (each cycle is 21 days)
- measure
- Trough plasma concentration [Ctrough]
- time Frame
- Day 1 to Cycle1Day15
- description
- The Tmax of Cycle1Day1 and Cycle1Day15 will be assessed, (each cycle is 21 days)
- measure
- Time to reach maximum plasma concentration [Tmax]
- time Frame
- Day 1 to Cycle1Day15
- description
- Duration of Response(DOR) based on independent radiology review by Independent Review Committee(IRC) and investigator according to RECIST 1.1
- measure
- Duration of Response(DOR)
- time Frame
- 25 months
- description
- Time to Response(TTR) based on independent radiology review by Independent Review Committee(IRC) and investigator according to RECIST 1.1
- measure
- Time to Response(TTR)
- time Frame
- 6 months
- description
- Time to Progress(TTP) based on independent radiology review by Independent Review Committee(IRC) and investigator according to RECIST 1.1 OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.
- measure
- Time to Progress(TTP)
- time Frame
- 25 months
- description
- Progression free Survival(PFS) based on independent radiology review by Independent Review Committee(IRC) and investigator according to RECIST 1.1
- measure
- Progression free Survival(PFS)
- time Frame
- 25 months
- description
- Intracranial Best overall response (BOR) based on independent radiology review by Independent Review Committee(IRC) and Investigator according to RANO for intracranial lesion
- measure
- Intracranial best overall response (IBOR)
- time Frame
- 25 months
Full study description
- brief Summary
- The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.
- detailed Description
- This is a Phase II, multicenter, single-arm, open label study of AB-106 in the Chinese patients with advanced NSCLC harboring ROS1 fusion gene.The study will be divided into two stages. First stage (Stage I) is to determine the clinical optimal dose of AB-106, which will be evaluated at two dose levels (400 mg QD and 600mg QD), and the safety, tolerability and pharmacokinetics of AB-106 will be evaluated at the same time; Second stage (Stage II) is to evaluate the efficacy and safety of AB-106 at the clinical optimal dose determined from Stage I. It is expected that 6 patients with advanced NSCLC harboring ROS1 fusion will be enrolled in the first stage. About 167 patients with ROS1 fusion will be enrolled in the second stage and divided into two treatment cohorts (Cohort A \& Cohort B). It is planned to enroll about 106 ROS1-TKI treatment naïve patients in Cohort A and about 67 crizotinib pre-treated patients in Cohort B. AB-106 will be administered 600mg once daily in 21-day cycles. Patients will continue with the study treatment until progression of disease as determined by the investigator. The frequency of tumor assessments is once every 2 treatment cycles through Cycle 9, then every 3 treatment cycles through Cycle 27 and every 4 treatment cycles thereafter.
Source references
- references
- citation
- Li W, Zhang Y, Fan H, Yu Q, Ran F, Chen W, Zhou C. Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study. J Clin Oncol. 2026 Jun 20;44(18):1670-1675. doi: 10.1200/JCO-26-00434. Epub 2026 Apr 21.
- pmid
- 42013573
- type
- DERIVED
- citation
- Perol M, Li W, Pennell NA, Liu G, Ohe Y, De Braud F, Nagasaka M, Felip E, Xiong A, Zhang Y, Fan H, Wang X, Li S, Lai RK, Ran F, Zhang X, Chen W, Bazhenova L, Zhou C. Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST. J Clin Oncol. 2025 Jun;43(16):1920-1929. doi: 10.1200/JCO-25-00275. Epub 2025 Apr 3.
- pmid
- 40179330
- type
- DERIVED
- citation
- Li W, Xiong A, Yang N, Fan H, Yu Q, Zhao Y, Wang Y, Meng X, Wu J, Wang Z, Liu Y, Wang X, Qin X, Lu K, Zhuang W, Ren Y, Zhang X, Yan B, Lovly CM, Zhou C. Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study. J Clin Oncol. 2024 Aug 1;42(22):2660-2670. doi: 10.1200/JCO.24.00731. Epub 2024 Jun 1.
- pmid
- 38822758
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-b0900a75aa288edb0698
- requested nct id
- NCT04395677
- primary nct id
- NCT04395677
- source kind
- fda_spl_label
- source record id
- 5154bda7-7ab4-4ad4-8fee-7fbe9ea692cc
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 7df7d143f8accb29f0d6d9d3b99d0affe33ede30d654d3e8822163f21f9075d6
- payload
- application numbers
- NDA219713
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-b0900a75aa288edb0698
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT04395677
- occurrences
- context exact
- d or metastatic NSCLC who received IBTROZI at a dose of 600 mg orally once daily, enrolled in two multicenter, single-arm, open-label clinical trials: TRUST-I (NCT04395677) or TRUST-II (NCT04919811). In both trials, patients were required to have histologically confirmed, locally advanced or metastatic, ROS1 -positive NSCLC, ECOG
- end
- 337
- exact text
- NCT04395677
- start
- 326
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/40/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 5154bda7-7ab4-4ad4-8fee-7fbe9ea692cc
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 1ab3efd1fbc0f6ba8e517d713302a760ab352b33101de7e8911065c19a5ecfb1
- spl effective time
- 20260323
- spl set id
- 51ac8e52-3269-4102-8dc8-dba22d82128c
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-bfaad8722ca868ba102f
- requested nct id
- NCT04395677
- primary nct id
- NCT04395677
- source kind
- fda_approval_notice
- source record id
- fda-0f7fd15d941ce1a4
- source file sha256
- ad7a671b07a45f07f1311e871659ba674dcececcfb8e6973eae1869716554891
- payload sha256
- b8732797b511f9191584aa9dab5854d6362e47dc6c40226e6cf00143af609719
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-bfaad8722ca868ba102f
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT04395677
- occurrences
- context exact
- as evaluated in patients with locally advanced or metastatic, ROS1-positive NSCLC enrolled in two multicenter, single-arm, open-label clinical trials, TRUST-I (NCT04395677) and TRUST-II (NCT04919811). The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naïve to treatment with a ROS1 tyrosine ki
- end
- 24304
- exact text
- NCT04395677
- start
- 24293
- offset unit
- unicode_code_points
- source event date
- 2025-06-11
- source file
- /tmp/cancer-full-research/updates/pages/fda-approves-taletrectinib-ros1-positive-non-small-cell-lung-cancer.html
- source file sha256
- ad7a671b07a45f07f1311e871659ba674dcececcfb8e6973eae1869716554891
- source json pointer
- Source null
- source kind
- fda_approval_notice
- source record id
- fda-0f7fd15d941ce1a4
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- ad7a671b07a45f07f1311e871659ba674dcececcfb8e6973eae1869716554891
- source title
- FDA approves taletrectinib for ROS1-positive non-small cell lung cancer
Preserved source evidence · Not medical advice